PROCESS FOR PRODUCING CISATRACURIUM AND ASSOCIATED INTERMEDIATES
    3.
    发明公开
    PROCESS FOR PRODUCING CISATRACURIUM AND ASSOCIATED INTERMEDIATES 审中-公开
    用于生产Cisatracurium及相关中间体

    公开(公告)号:EP2176227A1

    公开(公告)日:2010-04-21

    申请号:EP08738291.7

    申请日:2008-05-01

    申请人: Chemagis Ltd.

    IPC分类号: C07D217/10

    CPC分类号: C07D217/10

    摘要: The present invention provides a process of producing cisatracurium compounds, e.g., cisatracurium besylate, from isoquinolinium salts of the structural formula (VIIA) wherein X- is an anion and R is H or a C1-C6 alkyl, or an activated form of the carboxylic acid with 1,5-pentanediol to form a cisatracurium salt, optionally via an intermediate compound (VIII). The cisatracurium compounds can be purified using simple techniques to afford pure cisatracurium besylate without the need for HPLC purification.

    Preparation of fused polycyclic alkaloids by ring closure of azomethine ylides, novel compounds thereof and their use as chemotherapeutic agents
    4.
    发明公开
    Preparation of fused polycyclic alkaloids by ring closure of azomethine ylides, novel compounds thereof and their use as chemotherapeutic agents 失效
    稠合多环生物碱通过甲亚胺叶立德,其衍生物的环合和它们作为化疗剂的制备使用

    公开(公告)号:EP1621533A1

    公开(公告)日:2006-02-01

    申请号:EP05024198.3

    申请日:1998-05-01

    摘要: The invention provides compounds of general Formula (I)

    wherein,

    A is a cyclic group being an optionally substituted aryl group or an aromatic heterocyclic group; or
    A is a cyclic group R A1 R A2 C-CR A3 R A4 wherein R A2 and R A3 , together with the carbon atoms to which they are attached form an optionally substituted saturated or unsaturated carbocyclic or heterocyclic group and R A1 and R A4 are as defined below or together form a bond; or
    A is a non-cyclic group R A1 R A2 C-CR A3 R A4 wherein R A1 - R A4 are as defined below and R A2 and R A3 may optionally together form a bond;
    Z is a carbon or a heteroatom;
    n is selected from 0, 1, 2 or 3; and
    R A1-A4 , W, X and Y may be the same or different and each are selected from hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally protected hydroxy, optionally substituted amino, optionally substituted alkoxy, optionally substituted alkenoxy, optionally substituted alkynoxy, optionally substituted aryl, optionally substituted heterocyclyl, carboxy, carboxy ester, carboxamido, acyl, acyloxy, mercapto, optionally substituted alkylthio, halogen, nitro, sulfate, phosphate and cyano, or W and X, together with the nitrogen and carbon atoms to which they are attached, form a saturated or unsaturated nitrogen containing heterocyclic group which may be optionally substituted or optionally fused to a saturated or unsaturated carbocyclic group, aryl group or heterocyclic group;
    or pharmaceutically acceptable derivatives and salts, racemates, isomers and/or tautomers thereof;
    provided that the compound is not one selected from Lamellarin A-N, S-X; D, L, K, M, N-triacetate; I-acetate; G-trimethyl ether; or T, U, V, Y-20-sulphate. Such compounds are useful as chemotherapeutic agents.

    摘要翻译: 本发明提供了通式worin(I)的化合物中,A是被任选substituiertem芳基或芳香族杂环基的环状基团; 或A是一个环状基团R A1,R A2 C-CR A3 - [R A4 worin - [R A2和R A3,与碳原子一起与它们所连接形式在OPTIONALLY substituiertem饱和或不饱和碳环或杂环基,R A1和R A4 是下文定义的或一起形成一个键; 或A是一个非环状基R A1 A2 - [R C-CR A3 A4 - [R [R worin A1 - R的A4如下文所定义并且R A2和R A3可以任选地一起形成一个键; Z是碳或杂原子; n选自0,1,2或3中选择; 和R A1-A4,W,X和Y可以相同或不同,且各自选自氢,任选substituiertem烷基,任选substituiertem烯基,任选substituiertem炔基,任选保护的羟基,任选substituiertem氨基,任选substituiertem烷氧基,任选substituiertem 链烯氧基,任选substituiertem炔,任选substituiertem芳基,任选substituiertem杂环基,羧基,羧基酯,甲酰氨基,酰基,酰氧基,巯,任选substituiertem烷硫基,卤素,硝基,硫酸盐,磷酸盐和氰基,或W和X,的氮一起 和碳原子它们所连接,形成饱和或不饱和含氮其可以任选substituiertem或任选地稠合到杂环基团的饱和或不饱和的碳环基,芳基或杂环基团; 或药学上可接受的衍生物和盐,种族匹配,异构体和/或互变异构体; 提供DASS死化合物不是一个从片螺素A-N,S-X中选择; D,L,K,M,N-三乙酸酯; I-乙酸酯; G-三甲基醚; 或T,U,V,Y-20-硫酸盐。 搜索化合物作为化学治疗剂是有用的。

    VERFAHREN ZUR HERSTELLUNG VON N-ALLYLVERBINDUNGEN
    6.
    发明授权
    VERFAHREN ZUR HERSTELLUNG VON N-ALLYLVERBINDUNGEN 失效
    用于生产N-烯丙基化合物

    公开(公告)号:EP0640073B1

    公开(公告)日:1996-04-17

    申请号:EP93909543.6

    申请日:1993-05-05

    CPC分类号: C07D213/20

    摘要: A process is disclosed for preparing N-allyl compounds having general formula (I), in which (II) stands for a N-containing aromatic heterocycle; R?1, R3 and R4¿ represent independently from each other hydrogen or C¿1?-C4-alkyl; R?2¿ stands for hydrogen or methyl; n equals 1, 2, 3 or 4 and X- is an anion for rendering water-soluble. The process is characterized in that compounds having formula (II) are reacted in an aqueous medium with compounds having formula (III), in which A stands for a residue which can be split as an anion. These compounds are very suitable as brighteners for nickel-plating.

    Verfahren zur Herstellung von TCNQ-Komplexen
    8.
    发明公开
    Verfahren zur Herstellung von TCNQ-Komplexen 失效
    一种用于TCNQ复合物的制备方法。

    公开(公告)号:EP0138093A2

    公开(公告)日:1985-04-24

    申请号:EP84111214.7

    申请日:1984-09-20

    申请人: BAYER AG

    摘要: Die Erfindung betrifft ein Verfahren zur Herstellung von 7,7,8,8-Tetracyanochinodimethan enthaltenden Charge-Transfer-Komplexen durch Umsetzung von TCNQ mit organischen Kationiodiden oder durch Umsetzung von stickstoffhaltigen Heteroaromaten und tertiären Aminen mit H 2 TCNQ, in dem geringere Mengen Lösungsmittel verwendet werden als zur vollständigen Lösung des TCNQ erforderlich sind.

    摘要翻译: 本发明涉及一种用于通过用有机Kationiodiden或通过选择含有杂芳族化合物,并用H2TCNQ叔胺氮的反应TCNQ的反应含电荷转移络合物7,7,8,8-四氰基的制备方法在较低量的溶剂一起使用 必须完成TCNQ的解决方案。